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ABSTRACT 
     Fecal Calprotectin is released in colon by activated neutrophils. Investigation of diagnostic application of 
determination of fecal Calprotectin levels is considered by many researchers to compare between different 
colorectal diseases like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD). Due to 
the effect of nutrition habits on the inflammatory processes of bowel, the main goal of this study was to 
evaluate the level of fecal Calprotectin in healthy subjects in Iranian army personnel that have specific and 
the same nutrition habits, in comparison with non-military population and also make this test an in-house 
method in Army laboratories.  
In this study a prospective and sample collection method used available samples (Convenience sampling). 
We collected stool samples from 108 subjects from Army personnel and 108 samples from non-military 
Iranian population with corresponding data collection form. Determination of Calprotectin levels was done 
by specific third generation quantitative ELISA method and statistics were done using SPSS software.  
The results showed that mean Calprotectin level in two included groups were 26.1 micrograms per gram in 
Army personnel group and 25.4 micrograms per gram in non-military control subjects. Fecal Calprotectin 
level in two studied groups wasn’t significantly different. Despite the little increase in Calprotectin levels in 
Army personnel group compared with control group this difference wasn’t statistically significant (P>0.05).   
We can conclude that the nutrition habits of army personnel could cause effects on inflammatory processes 
in digestive system. Determination of fecal Calprotectin levels as a cost effective and non invasive test could 
be used by military physicians for early diagnosis of inflammation in personnel by routine tests subjects.   
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INTRODUCTION  
     Inflammation is one of the most common 
defense mechanisms of the human body and 
essentially is a part of non-specific immune 
response. General mechanism for regulating the 
inflammatory process can collide as the main 
cause of many chronic diseases including 
damages caused by digestive system autoimmune 
and inflammatory deficiencies [1-3].  
When inflammation occurs, inflammatory 
cytokines are released by white blood cells or 
Affect on the surrounding tissues. These 
cytokines can increase blood pressure in that area 
and cause a leak of liquid containing cytokines 
into the tissues and cause swelling or edema. 
Inflammatory process may stimulate nerves and 
cause pain[4].  
Inflammatory bowel diseases (IBD) are the 
chronic conditions that are recurrent symptoms 
associated with repetitive episodes that occurred 
in the digestive tract including Crohn’s Disease 
(CD) and Ulcerative Colitis (UC). Patients with 
inflammatory bowel disease (IBD) are experience 
types of diarrhea, abdominal pain and bloating, 
indigestion, rectal bleeding and weight loss. The 
main cause of inflammatory bowel disease is still 
quite unknown. But it is likely that a series of 
immunological factors, genetic and environmental 
(including natural microbial flora of the intestine) 
can cause these symptoms [2, 4].  
 





About two million people across Europe suffer 
from inflammatory bowel disease. Crohn's disease 
and Ulcerative Colitis are chronic and serious 
intestinal diseases that have severe, sudden and 
annoying effects on the patients’ quality of life. 
And finally will increase the possibility of 
malignant colon tumors in these individuals.  
When symptoms appear there are many 
similarities with the symptoms of functional 
bowel disorders such as IBS (irritable bowel 
syndrome); this makes accurate diagnosis very 
difficult for doctors [2, 4-7].  
Inflammatory diseases, including diseases that are 
debilitating, especially moderate and severe forms 
can cause many problems for patients. One of the 
difficult diagnosis and complex digestive diseases 
that gastrointestinal specialists are constantly 
faced with is How to distinguish and differentiate 
patients with IBS from other intestinal disorders 
with Organ complications such as inflammatory 
bowel diseases and colorectal cancer [8, 9].  
Between the two series of anomalies, there are 
common signs and symptoms such as abdominal 
pain, bloating and altered bowel habits and there 
are other clinical characteristics that lead the 
doctor suspected abnormalities of the organ origin 
including chronic bloody diarrhea and rectal 
bleeding. Although symptoms can guide doctors 
to diagnose diseases but most doctors follow a 
laboratory test to ensure they are having a more 
reliable diagnosis[10]. 
Among the tests that are done in order to include 
the total count of blood cells, Erythrocyte 
Sedimentation Rate and C - reactive protein test. 
By performing these tests can be largely ruled out 
the possibility of inflammatory diseases but the 
problem is that some organic bowel disease 
patients If only this measure be placed under test 
are wrongly diagnosed and this forced doctors to 
perform invasive procedures such as endoscopy 
and biopsy (biopsy) to ensure the absence of any 
organ complications in the intestine. Performing 
such invasive tests will impose many risks to the 
patients’ health and quality of life[11-14].  
There is some evidence about contribution of 
atherogenesis in inflammation so dietary fats may 
be proinflammatory. The low-fat, high-
carbohydrate diets applied bad effects on the 
inflammatory markers such as fecal Calprotectin 
[15]. In the present study, we aimed to explain 
whether the fixed and the similar diet of army 
personnel can adjust digestive system 
inflammation markers.  
Few studies have examined the protein levels of 
fecal Calprotectin has been done on Iranian 
population [16]. Given the importance and 
benefits of this laboratory test and to generate 
more data for future studies, we performed the 
present study to compare the fecal Calprotectin 
among healthy personnel of the armed forces with 
healthy people outside of the Systems of the 
Armed Forces.   
 
MATERIALS AND METHODS 
     For this Descriptive study, samples were 
collected from two study populations including 
108 healthy employees of the armed forces from 
one military unit with fixed and similar diet and 
108  age and sex matched healthy people outside 
of the armed forces with normal and home made 
diet (volunteers from the general population of the 
country). A questionnaire based on Rome III 
Criteria was filled for each person. Exclusion 
criteria for both groups was existence of any 
digestive system disorders such as inflammatory 
bowel disease, irritable bowel syndrome, chronic 
constipation and diarrhea and Other complications 
that are listed in the Rome III criteria. Fresh stool 
samples were collected of each person in special 
containers and were maintained until performing 
the tests at -70 ° C. fecal Calprotectin levels were 
determined using third generation specific ELISA 
kits (Hycult biotech, Netherlands) according to 
manufacturer's instructions. Shortly before the 
ELISA test, stool samples prepared using 
extraction solution according to protocol proposed 
by kit manufacturer. Statistical data analysis was 
performed using SPSS software version 13 and 
Student’s T test.   
 
RESULTS 
     In coordination with the military hospital 
laboratory, stool samples were obtained from 
personnel referring for their periodic tests. Fecal 
Calprotectin tests were performed on all samples 
to detect the average amount of protein in two 
 





studied groups. 108 army personnel were 
considered for sampling and to compare the 
results we prepared stool samples from one 
hundred and eight, age and sex matched Iranian 
healthy individuals. 
Results of laboratory tests and characteristics of 
study subjects are summarized in Table 1. As the 
data summarized in the table show, despite the 
amount of fecal Calprotectin was slightly higher 
in the group of army personnel in comparison 
with healthy individuals outside the military 
system, but this difference was not statistically 
significant. In order to achieve a better 
understanding of the statistical output, such as 
better hand out and see the many dimensions of 
data, data analysis diagram as in diagram (1) can 
be seen, would be useful. In this chart, the 
minimum and maximum values obtained for each 
study group is written in the side of the mean 
values. From this chart we can see that the 
scattering data on fecal Calprotectin levels of 
army personnel is greater than the general 
population's values. Also maximum calculated 
amount of fecal Calprotectin equal to 1.38 
micrograms per gram, and the minimum value 
equal to 1.14 micrograms per gram, was 
corresponded to army personnel group.  
 
 
Table1. Comparison of Fecal Calprotectin level in the general population with army personnel in both genders.  
Variable General Population Army Personnel P value 
Age (Mean ± SD ) 35 ± 6.6 36 ± 14.2 0.293 
Male / Female (n %) 68 (63%)/ 40 (37%) 68 (63%)/ 40 (37%) 1.000 

















Calprotectin level in the army personnel group Calprotectin level in the general population group
 
Figure1. Comparison of minimum, maximum and average fecal Calprotectin in the two study groups.   
 
DISCUSSION AND CONCLUSION 
     Many studies have been done on application of 
fecal Calprotectin level determination in different 
gastrointestinal diseases with similar symptoms. 
This study was the first report of such comparison 
among Iranian population. A study by Rezaei 
Tavirani and colleagues in 2008 has been done on 
comparison of the inhibitory effect of killing the 
cells (Cytotoxicity) of Calprotectin on two types 
of fibroblast cell lines. In this study selected cell 
lines were affected by different concentrations of 
purified Calprotectin; And the rate of cell 
 





proliferation in the presence of this active 
ingredient, in different time periods were 
measured using the MTT assay.  The very 
important result of this study was despite all the 
tested cells were fibroblast but their differential 
differences makes them to show different results 
in Calprotectin cytotoxicity at the same 
concentration and exposure time [16].   
Erbayrak and colleagues in 2009 were performed 
a study in Turkish population on the role of fecal 
Calprotectin levels in inflammatory bowel 
disease. They examined a total of 65 patients with 
inflammatory bowel disease and 20 healthy 
controls. The survey results showed that fecal 
Calprotectin levels in all controls were lower than 
the Cut-Off point (50 micrograms per gram of 
stool) Resulting in fecal Calprotectin can be 
strongly correlated with inflammation in the colon 
and rectum. The researchers were introduced the 
fecal Calprotectin test as a non-invasive method 
for evaluation and diagnosis process of the 
transition of macrophages into the colon lumen 
space and suggested that this test can be used to 
measure patient response to therapy and predict 
recurrence of inflammation in IBD patients [10].  
Kallel and colleagues in 2010, in Turkey, a study 
conducted on 53 patients with Crohn's disease. 
They aimed to use the measurement of fecal 
Calprotectin as a diagnostic predictor for 
individuals suffered from Crohn's disease in a 
one-year Follow up. Relapse of inflammation was 
observed in 10 patients among total 53 studied 
individuals. Fecal Calprotectin levels in the 
relapse group compared with non-relapse group 
was significantly higher. Average amount of fecal 
Calprotectin in relapse group was 380.5 
micrograms per gram and in the non-relapse 
group was 155 micrograms per gram. Obtained p-
value was less than 0.001 and shows a high 
significance level. According to this study 
presence of fecal Calprotectin more than 340 
micrograms per gram of stool, raises the chance 
of relapse up to 18 times. Fecal Calprotectin can 
be introduced as an independent factor to predict 
relapse of inflammation in patients with Crohn's 
disease [17].  
People with the same dietary, hygienic behaviors 
and health habits, such as army personnel have 
the same chance for the incidence of 
gastrointestinal diseases with unknown causes. 
Given the high importance of their professional 
duties the importance of rapid and accurate 
diagnosis of the diseases is more important. 
According to the results of the present study 
Calprotectin as a marker of intestinal 
inflammation in the army personnel in 
comparison with the general population of Iran 
was slightly higher. To achieve more reliable and 
applicable results this phenomenon needs further 
investigations on different populations. 
  
REFERENCES 
1. Baillet A. [S100A8, S100A9 and S100A12 
proteins in rheumatoid arthritis]. Rev Med 
Interne, 2010. 31(6): 458-461. 
2. Bamias G, Sugawara K, Pagnini C,Cominelli F. 
The Th1 immune pathway as a therapeutic target 
in Crohn's disease. Curr Opin Investig Drugs, 
2003. 4(11): 1279-1286. 
3. Blanchard EB, Lackner JM, Jaccard J, Rowell 
D, Carosella AM, Powell C, et al. The role of 
stress in symptom exacerbation among IBS 
patients. J Psychosom Res, 2008. 64(2): 119-128. 
4. Bouma G,Strober W. The immunological and 
genetic basis of inflammatory bowel disease. Nat 
Rev Immunol, 2003. 3(7): 521-533. 
5. Williams EA, Nai X,Corfe BM. Dietary intakes 
in people with irritable bowel syndrome. BMC 
Gastroenterol, 2011. 11(1): 9. 
6. Kay L, Jorgensen T,Jensen KH. The 
epidemiology of irritable bowel syndrome in a 
random population: prevalence, incidence, natural 
history and risk factors. J Intern Med, 1994. 
236(1): 23-30. 
7. Spiegel BM, Farid M, Esrailian E, Talley 
J,Chang L. Is irritable bowel syndrome a 
diagnosis of exclusion?: a survey of primary care 
providers, gastroenterologists, and IBS experts. 
Am J Gastroenterol, 2010. 105(4): 848-858. 
8. Isaksen B,Fagerhol MK. Calprotectin inhibits 
matrix metalloproteinases by sequestration of 
zinc. Mol Pathol, 2001. 54(5): 289-292. 
 





9. Roseth AG, Kristinsson J, Fagerhol MK, 
Schjonsby H, Aadland E, Nygaard K, et al. Faecal 
calprotectin: a novel test for the diagnosis of 
colorectal cancer? Scand J Gastroenterol, 1993. 
28(12): 1073-1076. 
10. Erbayrak M, Turkay C, Eraslan E, Cetinkaya 
H, Kasapoglu B,Bektas M. The role of fecal 
calprotectin in investigating inflammatory bowel 
diseases. CLINICS, 2009. 64(5): 421-425. 
11. Burkhardt K, Radespiel-Troger M, Rupprecht 
HD, Goppelt-Struebe M, Riess R, Renders L, et 
al. An increase in myeloid-related protein serum 
levels precedes acute renal allograft rejection. J 
Am Soc Nephrol, 2001. 12(9): 1947-1957. 
12. Camilleri M,Choi MG. Review article: 
irritable bowel syndrome. Alimentary 
Pharmacology & Therapeutics, 1997. 11(1): 3-15. 
13. Carroccio A, Iacono G, Cottone M, Di Prima 
L, Cartabellotta F, Cavataio F, et al. Diagnostic 
Accuracy of Fecal Calprotectin Assay in 
Distinguishing Organic Causes of Chronic 
Diarrhea from Irritable Bowel Syndrome: A 
Prospective Study in Adults and Children. Clin 
Chem, 2003. 49(6): 861-867. 
14. Tibble JA,Bjarnason I. Non-invasive 
investigation of inflammatory bowel disease. 
World J Gastroenterol, 2001. 7(4): 460-465. 
15. Kallio P, Kolehmainen M, Laaksonen DE, 
Pulkkinen L, Atalay M, Mykkänen H, et al. 
Inflammation markers are modulated by 
responses to diets differing in postprandial insulin 
responses in individuals with the metabolic 
syndrome. The American Journal of Clinical 
Nutrition, 2008. 87(5): 1497-1503. 
16. Rezaei-Tavirani M, Zali H, Nabai L, Toossi P, 
Zad FM,Yousof P. A comparative study of 
inhibitory effect of human calprotectin on the 
growth of human gingival fibroblast and foreskin 
fibroblast. Pak J Biol Sci, 2008. 11(6): 925-929. 
17. Kallel L, Ayadi I, Matri S, Fekih M, 
Mahmoud NB, Feki M, et al. Fecal calprotectin is 
a predictive marker of relapse in Crohn's disease 
involving the colon: a prospective study. 
European Journal of Gastroenterology & 
Hepatology, 2010. 22(3): 340-345. 
 
       24 
2424 
